NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -232.87 Million USD | -160.12% |
| 2022 | -89.52 Million USD | -101.93% |
| 2021 | -44.33 Million USD | -308.62% |
| 2020 | 21.25 Million USD | 2425.05% |
| 2019 | -914 Thousand USD | 97.29% |
| 2018 | -33.67 Million USD | 14.38% |
| 2017 | -39.32 Million USD | 65.9% |
| 2016 | -115.31 Million USD | -10.89% |
| 2015 | -103.99 Million USD | -29.74% |
| 2014 | -80.15 Million USD | -24.35% |
| 2013 | -64.45 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -41.52 Million USD | 19.72% |
| 2024 Q2 | -33.6 Million USD | 19.06% |
| 2024 Q3 | -32.09 Million USD | 4.51% |
| 2023 FY | -232.87 Million USD | -160.12% |
| 2023 Q2 | -62.66 Million USD | -4.0% |
| 2023 Q3 | -58.24 Million USD | 7.05% |
| 2023 Q4 | -51.71 Million USD | 11.21% |
| 2023 Q1 | -60.24 Million USD | -40.19% |
| 2022 Q1 | -806 Thousand USD | 96.56% |
| 2022 Q3 | -24.61 Million USD | -16.49% |
| 2022 Q4 | -42.97 Million USD | -74.63% |
| 2022 FY | -89.52 Million USD | -101.93% |
| 2022 Q2 | -21.12 Million USD | -2521.34% |
| 2021 Q4 | -23.39 Million USD | -173.6% |
| 2021 FY | -44.33 Million USD | -308.62% |
| 2021 Q1 | -88 Thousand USD | -100.73% |
| 2021 Q2 | -12.29 Million USD | -13871.59% |
| 2021 Q3 | -8.55 Million USD | 30.44% |
| 2020 FY | 21.25 Million USD | 2425.05% |
| 2020 Q4 | 12.09 Million USD | -19.5% |
| 2020 Q3 | 15.02 Million USD | 125.28% |
| 2020 Q2 | 6.66 Million USD | 297.22% |
| 2020 Q1 | -3.38 Million USD | -2324.34% |
| 2019 Q4 | 152 Thousand USD | -96.06% |
| 2019 Q1 | -6.11 Million USD | 29.39% |
| 2019 Q2 | 1.19 Million USD | 119.55% |
| 2019 FY | -914 Thousand USD | 97.29% |
| 2019 Q3 | 3.85 Million USD | 222.32% |
| 2018 Q3 | -5.24 Million USD | 25.96% |
| 2018 Q1 | -12.67 Million USD | -181.34% |
| 2018 FY | -33.67 Million USD | 14.38% |
| 2018 Q4 | -8.66 Million USD | -65.15% |
| 2018 Q2 | -7.08 Million USD | 44.11% |
| 2017 Q1 | -13.37 Million USD | 25.19% |
| 2017 Q2 | -15.53 Million USD | -16.13% |
| 2017 Q4 | -4.5 Million USD | 23.87% |
| 2017 Q3 | -5.91 Million USD | 61.89% |
| 2017 FY | -39.32 Million USD | 65.9% |
| 2016 Q1 | -31.93 Million USD | -4.35% |
| 2016 Q3 | -28.26 Million USD | 24.09% |
| 2016 Q4 | -17.87 Million USD | 36.75% |
| 2016 Q2 | -37.23 Million USD | -16.59% |
| 2016 FY | -115.31 Million USD | -10.89% |
| 2015 Q1 | -21.94 Million USD | 4.62% |
| 2015 FY | -103.99 Million USD | -29.74% |
| 2015 Q3 | -24.23 Million USD | 10.91% |
| 2015 Q2 | -27.2 Million USD | -23.97% |
| 2015 Q4 | -30.6 Million USD | -26.27% |
| 2014 FY | -80.15 Million USD | -24.35% |
| 2014 Q1 | -17.99 Million USD | 0.0% |
| 2014 Q2 | -21.23 Million USD | -18.03% |
| 2014 Q3 | -17.9 Million USD | 15.7% |
| 2014 Q4 | -23 Million USD | -28.51% |
| 2013 FY | -64.45 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | -303.811% |
| AngioDynamics, Inc. | -97.71 Million USD | -138.308% |
| AtriCure, Inc. | -26.68 Million USD | -772.728% |
| Avinger, Inc. | -16.63 Million USD | -1299.88% |
| Azenta, Inc. | -73.12 Million USD | -218.45% |
| BioLife Solutions, Inc. | -70.82 Million USD | -228.796% |
| The Cooper Companies, Inc. | 533.1 Million USD | 143.682% |
| Daxor Corporation | -177.07 Thousand USD | -131409.247% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | -1440.961% |
| Femasys Inc. | -14.5 Million USD | -1505.069% |
| GlucoTrack, Inc. | -7.1 Million USD | -3178.012% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 12395.143% |
| Hologic, Inc. | 882.6 Million USD | 126.385% |
| ICU Medical, Inc. | 22.82 Million USD | 1120.241% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 113.18% |
| KORU Medical Systems, Inc. | -10.26 Million USD | -2167.483% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 727.987% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -3274.662% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -3274.662% |
| Masimo Corporation | 136.5 Million USD | 270.601% |
| Microbot Medical Inc. | -9.85 Million USD | -2262.963% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 1686.855% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 287.883% |
| Nephros, Inc. | -1.59 Million USD | -14518.33% |
| NEXGEL, Inc. | -3.47 Million USD | -6597.44% |
| NEXGEL, Inc. | -3.47 Million USD | -6597.44% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | -126.525% |
| OraSure Technologies, Inc. | 54.07 Million USD | 530.611% |
| Pro-Dex, Inc. | 7.17 Million USD | 3346.48% |
| Pulse Biosciences, Inc. | -43.57 Million USD | -434.424% |
| Predictive Oncology Inc. | -13.92 Million USD | -1572.757% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | -8447.78% |
| QuidelOrtho Corporation | 139.1 Million USD | 267.412% |
| Repligen Corporation | 54.57 Million USD | 526.689% |
| Sanara MedTech Inc. | -4.21 Million USD | -5424.592% |
| STAAR Surgical Company | 28.09 Million USD | 928.807% |
| Sharps Technology, Inc. | -10.12 Million USD | -2199.576% |
| Utah Medical Products, Inc. | 16.77 Million USD | 1488.031% |
| DENTSPLY SIRONA Inc. | -85 Million USD | -173.965% |
| Jin Medical International Ltd. | 2.86 Million USD | 8221.685% |